ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0444

Prevalence of Frailty and Associated Factors in Patients with Vasculitis

Sebastian Sattui1, John Stadler2, Cristina Burroughs3, Kalen Larson2, Christine Yeung4, Peter Merkel5 and Robert Spiera6, 1University of Pittsburgh, Pittsburgh, PA, 2Vasculitis Foundation, Kansas City, MO, 3University of South Florida, Tampa, FL, 4University of Pennsylvania, Philadelphia, 5University of Pennsylvania, Philadelphia, PA, 6Hospital for Special Surgery, New York, NY

Meeting: ACR Convergence 2022

Keywords: ANCA associated vasculitis, Patient reported outcomes, quality of life, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Vasculitis – ANCA-Associated Poster I: Epidemiology, Outcomes, and Classification

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Frailty is a syndrome characterized by an increased vulnerability to stressors and is associated with disability and early mortality. Frailty may be accelerated in patients with vasculitis. The prevalence of frailty and factors associated with it in patients with vasculitis remains unexplored.

Methods: VascStrong is a longitudinal study utilizing the Vasculitis Patient-Powered Research Network (VPPRN), an internet-based prospective longitudinal cohort. Data elements collected included type of vasculitis, demographic, use of medications, and patient-reported outcomes including patient global assessment (PGA) and Patient-Reported Outcomes Measurement Information System (PROMIS).

Frailty was measured by the FRAIL scale, a self-report measure which queries on 5 domains: 1. Fatigue, 2. Resistance (inability to climb 10 stairs), 3. Ambulation (inability to walk several blocks), 4. Illnesses (≥5/11 comorbidities), and 5. Loss of Weight (≥5% weight loss in the last year). Patients were classified as robust, pre-frail, and frail based on 0, 1-2, or ≥ 3 criteria, respectively. Most recently collected PGA and PROMIS scores for anxiety, fatigue, depression, pain interference, pain intensity, and physical functioning domains were analyzed by frailty categories. A multivariable logistic regression was performed to identify factors independently associated with frailty in the entire cohort.

Results: The survey collected information from October 8, 2021-January 15, 2022, and 328 responses were included. The most common diagnosis was granulomatosis with polyangiitis (39.3%), followed by eosinophilic granulomatosis with polyangiitis (12.5%), microscopic polyangiitis (11.9%), and giant cell arteritis (7.6%). Patients had a mean age of 59.5 years and were predominantly female (71.6%) and non-Hispanic white.

Prevalence of robustness, pre-frailty, and frailty was 36.3%, 42.1%, and 21.6%, respectively. The majority of patients with each form of vasculitis were rated as frail or pre-frail. Patients with polyarteritis nodosa, cryoglobulinemic vasculitis, urticarial vasculitis, and Takayasu’s arteritis were more commonly pre-frail or frail, compared to patients with other types of vasculitis. Among the individual FRAIL domains, fatigue and resistance were the most frequent (47.0% and 29.6%, respectively) while illnesses was the least common (2.4%). Pre-frail and frail patients reported worse pain (intensity and interference), fatigue, depression, and physical function. In the multivariable logistic regression, frailty was independently associated with female sex (OR 2.78 [95% CI 1.29,5.89]), being overweight (OR 5.02 [95% CI 2.13,11.84]), and obesity (OR 7.34 [95% CI 3.25,16.57]).

Conclusion: Self-reported frailty or pre-frailty is prevalent in the majority of patients with multiple forms of vasculitis. Frailty is independently associated with female sex, overweight, and obesity. Future work will be focused on identifying factors affecting frailty trajectories and outcomes and identifying interventions to ameliorate frailty in patients with vasculitis.

Supporting image 1

Table 1. Characteristics of overall cohort and by frailty classification

Supporting image 2

Table 2. Patient-reported outcomes by frailty classification

Supporting image 3

Table 3. Multivariable logistic regression of factors associated with frailty


Disclosures: S. Sattui, AstraZeneca; J. Stadler, None; C. Burroughs, None; K. Larson, None; C. Yeung, None; P. Merkel, AbbVie, AstraZeneca, Boeringher-Ingelheim, Bristol-Myers Squibb, ChemoCentryx, Forbius, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Neutrolis, Takeda, CSL Behring, Dynacure, EMDSerono, Immagene, Jannsen, Kiniksa, Magenta, Novartis, Pfizer, Q32, Regeneron, Sparrow, Eicos, Electra, Kyverna, UpToDate; R. Spiera, GlaxoSmithKlein(GSK), Boehringer-Ingelheim, Corbus Pharmaceutical, InflaRx, AbbVie/Abbott, Sanofi, Novartis, Chemocentryx, Roche, Vera.

To cite this abstract in AMA style:

Sattui S, Stadler J, Burroughs C, Larson K, Yeung C, Merkel P, Spiera R. Prevalence of Frailty and Associated Factors in Patients with Vasculitis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/prevalence-of-frailty-and-associated-factors-in-patients-with-vasculitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-frailty-and-associated-factors-in-patients-with-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology